ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0806 • ACR Convergence 2022

    Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression

    Inés Pérez Sancristóbal1, María Paula Álvarez Hernández2, Silvia Sanchez - Ramon3, Cristina Martinez4, Eduardo de la Fuente3, Concepcion Morado4, Dalifer Freites Nuñez2, Benjamin Fernandez Gutierrez5 and Gloria Candelas4, 1Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, 4Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 5Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain

    Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
  • Abstract Number: 1525 • ACR Convergence 2022

    Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey

    Sakir Ahmed1, Naveen R2, John Pauling3, Darpan Thakare2, Chris Wincup4, Nicoletta Del Papa5, Gianluca Sambataro6, Fabiola Atzeni7, SIMONE PARISI8, Marcello Govoni9, Elena Bartoloni Bocci10, Gian Domenico Sebastiani11, Enrico Fusaro12, Marco Sebastiani13, Luca Quartuccio14, Franco Franceschini15, Pier Paolo Sainaghi16, Giovanni Orsolini17, Rossella De Angelis18, Maria Giovanna Danielli19, Vincenzo Venerito20, Parikshit Sen21, Minchul Kim22, Abraham Edgar Gracia-Ramos23, Akira Yoshida24, James B. Lilleker25, Vishwesh Agarwal26, Sinan Kardes27, Jessica Day28, Mrudula Joshi29, Marcin Milchert30, Tamer A Gheita31, Babur Salim32, Ioannis Parodis33, Albert Selva O’Callaghan34, Elena Nikiphorou35, Tulika Chatterjee22, Ai Lyn Tan36, Arvind Nune37, Lorenzo Cavagna38, Samuel Shinjo39, Nelly Ziade40, Johannes Knitza41, Hector Chinoy42, Oliver Distler43, Masataka Kuwana44, Rohit Aggarwal45, Latika Gupta46, Vikas Agarwal2 and Ashima Makol47, 1Kalinga Institute of Medical Sciences, Bhubaneswar, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3North Bristol NHS Trust, Bristol, United Kingdom, 4University College London, London, United Kingdom, 5Unità operativa complessa (UOC) Day Hospital Reumatologia via Gaetano Pini 9, Centro Specialistico Ortopedico Traumatologico, Gaetano Pini-CTO, Milano, Italy, 6Medico Immunologia e reumatologia presso, Artoreuma S.R.L., Cors S, Mascalucia, 7Rheumatology Unit, University of Messina, Messina, Italy, 8Italian Society for Rheumatology, Turin, Italy, 9S. Anna Hospital and University of Ferrara, Ferrara, Italy, 10Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, 11U.O.C. Reumatologia, Ospedale San Camillo-Forlanini,, Roma, 12Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, 13Azienda Policlinico di Modena, Modena, Italy, 14Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy, 15Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 16Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy, 17Department of Medicine, Rheumatology Unit, University of Verona, Verona, Verona, 18Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy, 19Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle, Marche, Italy, 20Department of Emergency and Organ Transplantations-Rheumatology Unit, University of Bari "Aldo Moro", Bari, Italy, 21Maulana Azad Medical College, New Delhi, India, 22University of Illinois College of Medicine Peoria, Peoria, IL, 23Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, 24Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 25The University of Manchester, Manchester, United Kingdom, 26Mahatma Gandhi Missions Medical College, Lucknow, India, 27Istanbul University, Istanbul, Turkey, 28Walter and Eliza Hall Institute, Melbourne, Australia, 29Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, 30Pomeranian Medical University in Szczecin, Szczecin, Poland, 31Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 32Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, 33Karolinska Institutet, Stockholm, Sweden, 34Hospital Universitari Vall d'Hebron, Barcelona, Spain, 35Leiden University Medical Center & King's College London, London, United Kingdom, 36University of Leeds, Leeds, United Kingdom, 37Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, 38Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, 39Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 40Saint-Joseph University, Beirut, Lebanon, 41Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 42The University of Manchester, Sale, United Kingdom, 43Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 44Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 45Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 46Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, 47Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (AIRDs) are considered more susceptible to break through infection (BI) following vaccination due to their immunosuppressed status and…
  • Abstract Number: 2193 • ACR Convergence 2022

    Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry

    Simon Galmiche1, Benjamin Thoreau2, Stéphane Bretagne3, Alexandre Alanio3, André Paugam4, Valérie Bru5, Sophie Cassaing6, Jean-Pierre Gangneux7, Hélène Guégan7, Loïc Favennec8, Alida Minoza9, Florent Morio10, Julie Bonhomme11, Guillaume Desoubeaux12, Odile Eloy13, Lilia Hasseine14, Milène Sasso15, Laurence Millon16, Anne-Pauline Bellanger16, Philippe Poirier17, Maxime Moniot17, Taieb Chouaki18, Antoine Huguenin19, Frédéric Dalle20, Bernard Bouteille21, Muriel Nicolas22, Nicole Desbois-Nogard23, Marie-Elisabeth Bougnoux24, François Danion25, Vincent Poindron26, Antoine Néel27, Karine Boukris-Sitbon28, Fanny Lanternier29 and Benjamin Terrier30, 1Institut Pasteur, Paris, France, 2AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, 3Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, 4Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, 5Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, 6Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, 7Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, 8French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, 9Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, 10Parasitologe – Mycologie, CHU de Nantes, Nantes, France, 11Microbiologie, CHU de Caen, Caen, France, 12Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, 13Microbiologie, Hôpital de Versailles, Le Chesnay, France, 14Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, 15Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, 16Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, 17Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, 18Mycologie – parasitologie, CHU d’Amiens, Amiens, France, 19Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, 20Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, 21Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, 22Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, 23Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, 24Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, 25Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 27CHU de Nantes, Nantes, France, 28Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, 29Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, 30National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
  • Abstract Number: 0398 • ACR Convergence 2022

    Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection

    Benjamin Naovarat1, John Reveille1, Mark Hwang2, Francis Williams3 and Gloria Salazar4, 1University of Texas McGovern Medical School, Houston, TX, 2McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 3Specialists for Health/Wellmed, Shavano Park, TX, 4University of Texas Medical School at Houston/McGovern Medical School, Houston, TX

    Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…
  • Abstract Number: 0835 • ACR Convergence 2022

    Temporal Trends in Prosthetic Joint Infection

    Anne Bass1, Yi Zhang,2, Peter Sculco2, huong do2, Kayla Glaser2, alberto Carli2, Mark Figgie2 and Susan Goodman2, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Prosthetic joint infection (PJI) is a dreaded complication of total knee replacement (TKR) that usually requires removal of the prosthesis, treatment with antibiotics and…
  • Abstract Number: 1592 • ACR Convergence 2022

    Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades

    Rudrarpan Chatterjee, Sarit Sekhar Pattanaik, Durga P Misra, Vikas Agarwal, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We assessed the incidence and risk factors for major infections…
  • Abstract Number: 2218 • ACR Convergence 2022

    Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis

    Namrata Singh1, Laura Gold2, Katherine Wysham3, James Andrews2, Pankti Reid4, Una Makris5, Bryant England6, Jiha Lee7, Michael George8, Joshua Baker9, Jeffrey Jarvik2, Patrick Heagerty2 and Siddharth Singh10, 1University of Washington, Bellevue, WA, 2University of Washington, Seattle, WA, 3VA Puget Sound/University of Washington, Seattle, WA, 4University of Chicago Medical Center, Chicago, IL, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6University of Nebraska Medical Center, Omaha, NE, 7University of Michigan, Ann Arbor, MI, 8University of Pennsylvania, Philadelphia, PA, 9University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 10University of California San Diego, San Diego

    Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
  • Abstract Number: 0535 • ACR Convergence 2022

    Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’

    Duncan Porter1, Sahil Jain2 and Fraser Morton3, 1Gartnavel General Hospital, Bearsden, United Kingdom, 2Gartnavel General Hospital, Glasgow, Scotland, United Kingdom, 3University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…
  • Abstract Number: 0840 • ACR Convergence 2022

    Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy

    Kinjal Vasvada, Laith Jazrawi and Jonathan Samuels, NYU Langone Health, New York, NY

    Background/Purpose: Recent literature suggests that rheumatic disease patients hold most immunosuppressive (IS) medications before and after joint replacement surgery, to prevent infections and other complications.…
  • Abstract Number: 1593 • ACR Convergence 2022

    Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample

    Rashmi Dhital1, Monica Guma2, Dilli Poudel3 and Kenneth Kalunian4, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3Indiana Regional Medical Center, Indiana, PA, 4University of California San Diego, La Jolla, CA

    Background/Purpose: Infection is the leading cause of hospitalization and mortality in SLE. Care of young adults (YA) with SLE is particularly challenging, with higher mortality…
  • Abstract Number: 2273 • ACR Convergence 2022

    Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study

    Amy Mudano1, Gary Cutter2, Ted Mikuls3, Geoffrey Thiele4, Mark Law4, Bart Hamilton4, Michael Zikry5, Kelly Y. Chun6, Monique Bastidas7, Michael George8, Lisa Williams9, Kevin Winthrop10, Mark Busch11, Stanley Cohen12, Roman Czubatyj13, Rajesh Kataria14, Reshma Khan15, Soha Mousa16, Jose Pando17, Elizabeth Perkins18, Shanmugapriya Reddy19, Delfin Santos20, Joy Schechtman21, Frank Scott22, Sucharitha Shanmugam23, Atul Singhal24, John Tesser25, John Tower26, Swamy Venuturupalli27, Sean Joseph Wollaston28, Conrad Ziembinski29 and Jeffrey Curtis30, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5LabCorp, Burlington, NC, 6Labcorp, Calabasas, CA, 7LabCorp, Northridge, CA, 8University of Pennsylvania, Philadelphia, PA, 9Illumination Heath, Hoover, AL, 10Oregon Health & Science University, Portland, OR, 11Family Arthritis Center-Jupiter, Jupiter, FL, 12Metroplex Clinical Research Center, Pittsburgh, PA, 13Arthritis Physicians LLC, Rochester Hills, MI, 14Southern Ohio, Wheelersburg, OH, 15Palm Beach Rheumatology and Wellness, Jupiter, FL, 16Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, 17Rheumatology Consultants of DE, Lewes, DE, 18Rheumatology Care Center, Hoover, AL, 19Southwest Florida Rheumatology, Riverview, FL, 20Rochester Rheumatology, Rochester Hills, MI, 21SunValley Arthritis Center, Peoria, AZ, 22Arthritis Medical Center, Arroyo Grande, CA, 23Rheumatology and Arthritis Care Center, Exton, PA, 24Southwest Rheumatology Research, Mesquite, TX, 25Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 26Arthritis Physicians LLC, Rochester, MI, 27Cedars-Sinai Medical Center, Los Angeles, CA, 28Rheumatology Associates, North Hollywood, CA, 29CZ Rheumatology, Coral Springs, FL, 30Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
  • Abstract Number: L16 • ACR Convergence 2021

    Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository

    Jasvinder Singh1, Namrata Singh2, Alfred Anzalone3, Amy Olex4, Jing Sun5, Vithal Madhira6 and Rena Patel7, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Washington, Bellevue, WA, 3University of Nebraska, Omaha, NE, 4Virginia Commonwealth University, Richmond, VA, 5Johns Hopkins University, Baltimore, MD, 6Palila Software, Reno, NV, 7Unviersity of Washington, Seattle, WA

    Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
  • Abstract Number: 0252 • ACR Convergence 2021

    Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis

    Rajesh Kanumuri1, Suma Balan2, Vishal Marwaha2, Sajitha Krishnan2 and Pranav Chickermane2, 1Amrita Institute of Medical Sciences, Guntur, India, 2Amrita Institute of Medical Sciences, Kochi, India

    Background/Purpose: Fever is the most common presentation of systemic juvenile idiopathic arthritis (SJIA) and it is difficult to predict whether the fever is due to…
  • Abstract Number: 0984 • ACR Convergence 2021

    Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up

    Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA

    Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
  • Abstract Number: 1684 • ACR Convergence 2021

    Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Andra R Bălănescu1, Gustavo Citera2, Virginia Pascual-Ramos3, Carol A Connell4, David Gold5, All-shine Chen4, Harry Shi6, Andrea B Shapiro7, Janet Pope8 and Hendrik Schulze-Koops9, 1“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Peapack, NJ, 8University of Western Ontario, London, ON, Canada, 9Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany

    Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology